通过全面的基因组分析来确定不确定的BRCA1/2变异的优先级框架
Hikaru Nakahara1, Hiroaki Niitsu2, Asuka Toshida1
1Department of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan.
European journal of human genetics : EJHG
|March 1, 2026
概括
综合基因组分析 (CGP) 识别了不确定的重要性 (VUS) 的BRCA1/2变异. 整合in silico和功能数据的新框架优先考虑这些VUS,帮助临床解释遗传癌症风险.
科学领域:
- 基因组医学是基因组医学.
- 癌症基因组学 癌症基因组学
- 临床遗传学 临床遗传学
背景情况:
- 综合基因组分析 (CGP) 提高了癌症变异检测超越传统方法.
- 对于遗传性乳腺和卵巢癌 (HBOC) 来说,BRCA1/2基因分析至关重要,但面临着不确定的意义 (VUS) 变异的挑战.
研究的目的:
- 开发和验证一个系统的框架来优先考虑和解释通过CGP发现的不确定的意义的BRCA1/2变体 (VUS).
- 在现实环境中评估该框架的临床实用性.
主要方法:
- 分析了来自日本机构的2172个CGP测试.
- 使用十种in silico预测工具和功能证据的组合,对BRCA1/2 VUS进行系统的优先排序.
- 特定变异的功能分析,包括BRCA2:c.67G>C (p.D23H).
主要成果:
- 在526个确定的BRCA1/2变异中,153个被归类为VUS.
- 优先级框架将VUS缩小到10个候选变体 (2个拼接站点,8个错误).
- 对BRCA2:c.67G>C的功能分析表明功能丧失,患者数据支持其在同源重组缺陷中的临床相关性.
结论:
- 开发的整合性框架为从CGP数据中优先考虑和解释BRCA1/2 VUS提供了概念验证.
- 这种方法促进了CGP发现遗传性癌症倾向的临床实施.
- 该方法可能适用于其他癌症倾向基因.
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
9.9K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.9K
Pharmacogenomics: Identification of New Drug Targets
53
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
53
Genome-wide Association Studies-GWAS
16.0K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
16.0K


